Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.31 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3173578 | 0.60 | KDM4E (0.33) | ALDH1A1MAPT | |
| SCHEMBL28084853 | 0.58 | TSHR (0.34) | MAPT | |
| SCHEMBL20364311 | 0.57 | RAB9A (0.40) | ALDH1A1MAPTRAB9A | |
| SCHEMBL28076213 | 0.56 | KDM4E (0.30) | — | |
| SCHEMBL28533649 | 0.55 | — | — | |
| SCHEMBL7614894 | 0.55 | PKM (0.51) | ALDH1A1 | |
| SCHEMBL27487805 | 0.54 | — | — | |
| SCHEMBL28177241 | 0.54 | — | — | |
| SCHEMBL24205457 | 0.53 | LMNA (0.32) | ALDH1A1 | |
| SCHEMBL27322756 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010049-A1 | Novel Tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-01-14 | — | — | US | claimed |
| US-20100010049-A1 | Novel Tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010049-A1 | Novel Tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof | TYR, MITF, MAOA | ALDH1A1 69/4885MAPT 702/4885PPARG 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.